Quantinno Capital Management LP Acquires 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 178.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,744 shares of the biopharmaceutical company’s stock after purchasing an additional 42,158 shares during the quarter. Quantinno Capital Management LP’s holdings in Celldex Therapeutics were worth $2,085,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in CLDX. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Quantbot Technologies LP bought a new stake in shares of Celldex Therapeutics in the 3rd quarter valued at $63,000. Kestra Advisory Services LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $98,000. Finally, Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics during the 2nd quarter valued at $125,000.

Celldex Therapeutics Trading Up 3.0%

Celldex Therapeutics stock opened at $42.97 on Tuesday. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of -9.88 and a beta of 0.87. The firm’s fifty day moving average price is $35.45 and its two-hundred day moving average price is $31.70. Celldex Therapeutics, Inc. has a 1-year low of $19.72 and a 1-year high of $43.21.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.12. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.73 million. On average, research analysts forecast that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CLDX. Canaccord Genuity Group cut their target price on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Cantor Fitzgerald decreased their price target on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Guggenheim upped their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 20th. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Finally, HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $55.46.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.